A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. / Naimi, R M; Madsen, K B; Askov-Hansen, C; Brandt, C F; Hartmann, B; Holst, Jens Juul; Mortensen, P B; Jeppesen, P B.
In: Regulatory Peptides, Vol. 184, No. 10, 10.06.2013, p. 47-53.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients
AU - Naimi, R M
AU - Madsen, K B
AU - Askov-Hansen, C
AU - Brandt, C F
AU - Hartmann, B
AU - Holst, Jens Juul
AU - Mortensen, P B
AU - Jeppesen, P B
N1 - Copyright © 2013 Elsevier B.V. All rights reserved.
PY - 2013/6/10
Y1 - 2013/6/10
N2 - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.
AB - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.
U2 - 10.1016/j.regpep.2013.03.023
DO - 10.1016/j.regpep.2013.03.023
M3 - Journal article
C2 - 23501043
VL - 184
SP - 47
EP - 53
JO - Regulatory Peptides
JF - Regulatory Peptides
SN - 0167-0115
IS - 10
ER -
ID: 45842300